

Received SEC

OCT 06 2015

Washington, DC 20549



805 King Farm Blvd  
Rockville, MD 20850

William Slattery, CFA  
Vice President  
Listing Qualifications

CATINAS  
001-37581

By Electronic Mail

October 6, 2015



15008056

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on October 2, 2015 The Nasdaq Stock Market (the "Exchange") received from Aclaris Therapeutics, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, \$0.00001 par value per share

We further certify that the security described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

*William Slattery*